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cAMP-Binding Site of PKA as a Molecular Target
of Bisabolangelone against Melanocyte-Specific
Hyperpigmented Disorder
Eunmiri Roh1, Cheong-Yong Yun1, Ji Young Yun1, Dongsun Park2, Nam Doo Kim3, Bang Yeon Hwang1,
Sang-Hun Jung4, Sun Ki Park5, Yun-Bae Kim2, Sang-Bae Han1 and Youngsoo Kim1
Microphthalmia-associated transcription factor (MITF) is inducible in response to cAMP and has a pivotal role in
the melanocyte-specific expression of tyrosinase for skin pigmentation. Here we suggest that the cAMP-binding
site of protein kinase A (PKA) is a target in the inhibition of the melanogenic process in melanocytes, as
evidenced from the molecular mechanism of small molecules such as bisabolangelone (BISA) and Rp-adenosine
30,50-cyclic monophosphorothioate (Rp-cAMPS). BISA is a sesquiterpene constituent of Angelica koreana, a plant
of the Umbelliferae family, whose roots are used as an alternative medicine. BISA competitively inhibited cAMP
binding to the regulatory subunit of PKA and fitted into the cAMP-binding site on the crystal structure of PKA
under the most energetically favorable simulation. In a-melanocyte-stimulating hormone (a-MSH)–activated
melanocytes, BISA and Rp-cAMPS nullified cAMP-dependent PKA activation, dissociating catalytic subunits from
an inactive holoenzyme complex. They resultantly inhibited cellular phosphorylation of the cAMP-responsive
element-binding protein (CREB) or another transcription factor SOX9, thus downregulating the expression of
MITF or the tyrosinase gene with decreased melanin production. Taken together, this study defined the
antimelanogenic mechanism of BISA or Rp-cAMPS with a notable implication of the cAMP-binding site of PKA as
a putative target ameliorating melanocyte-specific hyperpigmented disorder.
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INTRODUCTION
Epidermal melanocytes synthesize melanin pigments and
transfer them to keratinocytes in a complex process known
as melanogenesis for skin pigmentation (Slominski et al.,
2004). Melanin pigments are produced in melanosomes, and
their types are dependent on melanogenic enzymes and the
availability of substrates. Tyrosinase is absolutely required in
the biosynthetic pathways of black–brown eumelanins and
yellow–red pheomelanins, in which it catalyzes the initial
rate-limiting step, L-tyrosine to dapaquinone, through two
distinct activities of tyrosine hydroxylase and dopa oxidase
(Olivares and Solano, 2009).
In humans, second messenger cAMP has an important
role in melanogenesis. a-Melanocyte-stimulating hormone
(a-MSH) and other cAMP elevators, including forskolin and
3-isobutyl-1-methylxanthine, stimulate melanin production in
melanocytes (Busca and Ballotti, 2000). a-MSH specifically
binds to the G protein–coupled melanocortin type I receptor,
which leads to activation of adenylate cyclase (Le Pape et al.,
2008). Forskolin directly activates adenylate cyclase, and 3-
isobutyl-1-methylxanthine inhibits phosphodiesterase in the
cAMP metabolism. Intracellular cAMP activates protein kinase
A (PKA) from an inactive holoenzyme complex consisting of a
regulatory subunit dimer bound to two catalytic subunits
(Kim et al., 2007; Taylor et al., 2008). Regulatory subunits of
PKA have been identified as four isoforms (RIa, RIb, RIIa, and
RIIb) and catalytic subunits as three isoforms (Ca, Cb, and Cg)
(Brandon et al., 1997; Skalhegg and Tasken, 2000). The
regulatory isoforms possess a conserved and well-defined
domain structure comprising a dimerization domain at the
N-terminus, two tandem cAMP-binding sites (designated A
and B) at the C-terminus, and an interconnecting linker region
that docks to the active site cleft of the catalytic subunit (Diller
et al., 2001; Zawadzki and Taylor, 2004). Each regulatory
isoform cooperatively binds two cAMP molecules, first to the
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B site followed by a second cAMP binding to the A site, which
concomitantly releases the catalytic subunit, thereby allowing
phosphorylation of PKA substrates such as cAMP-responsive
element-binding protein (CREB) and SOX9 (Berman et al.,
2005; Passeron et al., 2007; Sands and Palmer, 2008).
Phospho (p)-CREB and SOX9 are active indexes in the
upregulation of microphthalmia-associated transcription
factor (MITF), a basic helix-loop-helix protein crucial for
melanocyte differentiation and pigmentation (Passeron et al.,
2007; Liu and Fisher, 2010; Vachtenheim and Borovansky,
2010). In turn, MITF binds to the M box containing CATGTG
motifs in the promoter region of the tyrosinase gene for
transcriptional activation, thereby leading to melanin
biosynthesis (Kondo and Hearing, 2011).
Beyond MITF induction, cAMP affects post-translational
modification of MITF as another control point of melanogen-
esis. Intracellular cAMP inhibits phosphatidylinositol 3-kinase
(PI3K)/protein kinase B (AKT), which stimulates glycogen
synthase kinase 3b (GSK3b) activity by decreasing p-GSK3b
levels (Khaled et al., 2002, 2003). GSK3b phosphorylates
the Ser-298 residue of MITF, enhancing MITF affinity to the
M box for transcriptional activation of the tyrosinase
gene (Khaled et al., 2002). However, cAMP stimulates the
classical mitogen-activated protein kinase pathway, in which
extracellular signal–regulated kinase (ERK) phosphorylates the
Ser-73 residue of MITF and ribosomal S6 kinase 1 phosphor-
ylates the Ser-409 residue of MITF, eventually leading to
proteasome-mediated MITF degradation (Englaro et al., 1995;
Wu et al., 2000).
Abnormal accumulation and biosynthesis of melanin
pigments are responsible for skin disorders such as melasma,
freckles, and senile lentigo (Ortonne and Passeron, 2005;
Young Kang and Ortonne, 2009). These hyperpigmented
disorders can be substantially ameliorated by treatment with
arbutin or other tyrosinase inhibitors (Maeda and Fukuda,
1996; Solano et al., 2006). Bisabolangelone (BISA, Figure 1a)
was previously identified as the major antimelanogenic con-
stituent of Angelica koreana, a herbal medicine from the
Umbelliferae family (Roh et al., 2011). BISA inhibits a-MSH-
induced melanin production in B16 melanoma cells or melan-
a melanocytes, in which the sesquiterpene compound
decreases a-MSH-inducible protein levels of tyrosinase (Roh
et al., 2011). In the current study, we aimed to elucidate a
primary target of BISA for antimelanogenic activity, focusing
on the tyrosinase levels in cAMP-elevated melanocytes.
Indeed, BISA downregulated the expression of melanogenic
genes, such as MITF and tyrosinase, by direct blockade of the
cAMP binding to the PKA holoenzyme, suggesting a unique
molecular target in the treatment of melanocyte-specific
hyperpigmented disorder.
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Figure 1. Effects of bisabolangelone (BISA) on melanin production. (a) The chemical structure of BISA. (b) B16 cells were stimulated with a-melanocyte-
stimulating hormone (a-MSH) for 3 days in the presence of BISA, 5,6-dihydro-6-hydroxy-bisabolangelone (dhh-BISA), Rp-adenosine 30,50-cyclic
monophosphorothioate (Rp-cAMPS), or H-89. (c) Melan-a cells were stimulated with a-MSH for 4 days in the presence of BISA or dhh-BISA. (d) Human epidermal
melanocytes originating from neonatal foreskin were stimulated with a-MSH for 6 days in the presence of BISA or Rp-cAMPS. The numbers of cells were counted,
and melanin contents were measured with synthetic melanin as a standard. Data are mean±SD of three to five separate experiments. #Po0.05 vs. media
alone-added group. *Po0.05 vs. a-MSH alone-stimulated group.
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RESULTS
BISA inhibits melanin production in cAMP-elevated melanocytes
BISA (Figure 1a) and its saturated derivative 5,6-dihydro-6-
hydroxy-bisabolangelone (dhh-BISA, Supplementary Figure S1
online) inhibited melanin production in a-MSH-activated B16
or melan-a cell lines with similar levels of effectiveness
(Figure 1b and c), suggesting that the electrophilic moiety of
BISA with an a,b-unsaturated carbonyl structure might be
nonessential for its antimelanogenic action. Rp-adenosine
30,50-cyclic monophosphorothioate (Rp-cAMPS; Supple-
mentary Figure S1 online) and H-89 also inhibited a-MSH-
induced melanin production in B16 cells (Figure 1b).
Rp-cAMPS is a cell-permeable cAMP antagonist inhibiting
PKA activation (Dostmann et al., 1990; Wu et al., 2004), and
H-89 is a PKA inhibitor targeting the catalytic activity after
dissociation from an inactive holoenzyme complex (Lochner
and Moolman, 2006). Moreover, BISA inhibited a-MSH-
induced melanin production in human epidermal melano-
cytes originating from neonatal foreskin, as did Rp-cAMPS
(Figure 1d). We next examined whether BISA can affect
melanin production in melanocytes stimulated with other
cAMP elevators including N6,20-O-dibutyryl (db)-cAMP as a
cell-permeable cAMP-mimicking agonist. BISA inhibited db-
cAMP-, forskolin-, or 3-isobutyl-1-methylxanthine-induced mel-
anin production in B16 cells without affecting the viability of
melanocytes (Supplementary Figure S2 online). To understand
the in vivo efficacy of BISA, we carried out UV irradiation–
induced skin pigmentation in guinea pigs, in which cAMP is
also involved as a key messenger (D’Orazio and Fisher, 2011).
Dermal treatment with BISA reduced a visible pigmentation and
increased a whitening index (DL value) as compared with the
vehicle group (Supplementary Figure S3 online).
BISA inhibits cAMP-dependent PKA activation
BISA itself did not affect the cAMP levels in a-MSH-activated
B16 cells (Figure 2a), excluding its direct effect on melano-
cortin type I receptor-mediated cAMP production. To elucidate
a primary target for antimelanogenic activity, we tested
whether BISA can affect the cAMP-induced proximal
signaling event, PKA activation, by dissociating the catalytic
subunit from an inactive holoenzyme complex. B16 cells were
stimulated with a-MSH in the presence of BISA. Whole-cell
extracts were subjected to immunoprecipitation with antisera
against the regulatory subunits of PKA, such as anti-PKA (RI)
and anti-PKA (RIIb), in which the anti-PKA (RI) antibody
recognized the regulatory isoforms RIa and RIb of PKA.
The immunoprecipitates were then probed with anti-PKA
(Ca) antibody to detect the coprecipitation of the catalytic sub-
unit. Upon exposure to a-MSH alone, PKA (Ca) was markedly
dissociated from the regulatory subunits RIa/RIb or RIIb
(Figure 2b and c). BISA inhibited a-MSH-induced dissociation
of PKA (Ca) from RIa/RIb or RIIb (Figure 2b and c). Moreover,
Rp-cAMPS inhibited a-MSH-induced dissociation of PKA (Ca)
from RIIb, whereas H-89 was not effective (Figure 2c).
We next asked whether the dissociation of the catalytic
subunit of PKA from an inactive holoenzyme complex is
WB
PKA (Cα)
WB
PKA (Cα)
PKA (RIIβ)PKA (RIβ)
PKA (RIα)
IP: PKA (RI) IP: PKA (RIIβ)
2,700
1,800
900
0
21,000
14,000
7,000
0P
KA
 a
ct
iv
ity
 (c
.p.
m
.)
PK
A 
ac
tiv
ity
 (c
.p.
m
.,
 ×
10
–
3 )
210
140
70
0
BISA
Cellular PKA Cell-free PKA
**
*
*
*
*
#
α-MSH (100 nM)
(μM)
– 10 30 50 100–
BISA
RP-cAMPS
α-MSH (100 nM)
Catalytic subunit, rhPKA (50 ng)
– – – – – – 100 300
(μM)
(μM)
– – –3 10 30 100–
BISA
α-MSH (100 nM)
(μM)
– 10 30 50 100– BISA
H-89
RP-cAMPS
100
300
10
– –
–
–
–
––
–
–
–
–
α-MSH (100 nM)
(μM)
(μM)
(μM)
–
BISA
H-89
RP-cAMPS
10030103 – ––
300– – – – ––
10– – – – ––
(μM)
(μM)
(μM)
cA
M
P 
le
ve
l (p
mo
l m
l–1
)
#
Figure 2. Effects of bisabolangelone (BISA) on protein kinase A (PKA) activation. B16 cells were pretreated with BISA for 2 hours and stimulated with
a-melanocyte-stimulating hormone (a-MSH) for 20 minutes in the presence of BISA. (a) Cell extracts were subjected to ELISA to determine cAMP levels. In another,
cell extracts were subjected to immunoprecipitation (IP) with (b) anti-PKA (RI) antibody or (c) anti-PKA (RIIb) antibody, and these IP complexes were then probed
with anti-PKA (Ca) for western blot analysis (WB). (d) B16 cells were pretreated with BISA or Rp-adenosine 30,50-cyclic monophosphorothioate (Rp-cAMPS) for
2 hours and stimulated with a-MSH for 30 minutes in the presence of BISA or Rp-cAMPS. Cell extracts were used for kinase assay. (e) Cell-free rhPKA with catalytic
subunit only was treated with BISA, Rp-cAMPS, or H-89 for 10 minutes. PKA activity was measured by monitoring the incorporation of [32P] from cofactor
[g-32P]ATP onto the substrate Kemptide. Data are mean±SD of three separate experiments. (a, d) #Po0.05 vs. media alone-added group . (d) *Po0.05 vs. a-MSH
alone-stimulated group (e) or rhPKA alone-containing group. c.p.m., counts per minute.
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correlated with its kinase activity. Upon exposure to a-MSH
alone, B16 cells increased the kinase activity of PKA (Figure 2d).
BISA inhibited a-MSH-induced PKA activity in cells, in which
Rp-cAMPS was also effective (Figure 2d). To understand
whether BISA can directly interact with the catalytic subunit
of PKA, we determined the in vitro kinase activity of PKA with
the catalytic subunit only. BISA or Rp-cAMPS did not affect the
catalytic subunit–mediated kinase activity of PKA in cell-free
reactions, but H-89 inhibited directly (Figure 2e). Therefore,
BISA can inhibit a-MSH-induced PKA activation, whose
mechanism of action is similar to that of Rp-cAMPS as a
PKA-directed cAMP antagonist (Le Pape et al., 2008).
BISA competitively inhibits 8-[u-575]-cAMP binding to the
regulatory subunit of PKA
Fluorescent 8-[j-575]-cAMP specifically probes the cAMP-
binding A and B sites on the regulatory subunits (RIa, RIIa, and
RIIb) of PKA (Moll et al., 2008). 8-[j-575]-cAMP consistently
increased its fluorescence values upon binding to the RIIb
of PKA in cell-free reactions, as compared with basal levels
(Figure 3a and b). Treatment with nonfluorescent BISA dose-
dependently decreased the fluorescence intensity of 8-[j-575]-
cAMP (Figure 3a), indicating displacement of 8-[j-575]-cAMP
from the complexes with RIIb. This mechanism of action was
reversible because the fluorescence intensity was recovered in
the pretreatment with BISA followed by competitive titration
with excess 8-[j-575]-cAMP (Supplementary Figure S4 online).
Moreover, dhh-BISA and Rp-cAMPS inhibited 8-[j-575]-cAMP
binding to RIIb (Figure 3b). However, BISA or dhh-BISA did not
affect the basal fluorescence spectra of 8-[j-575]-cAMP in the
absence of RIIb (data not shown).
On the basis of the evidence that BISA competitively
inhibited 8-[j-575]-cAMP binding to the regulatory subunit
RIIb of PKA as well as a-MSH-induced PKA activation by
blocking the dissociation of the catalytic subunit from reg-
ulatory subunits (RIa/RIb, and RIIb), we proposed a docking
model of BISA to the crystal structure of RIIb of PKA (Diller
et al., 2001; Zawadzki and Taylor, 2004). BISA was well fitted
into the cAMP-binding A site of RIIb with close contacts to
Ile-180, Tyr-213, Gly-220, Glu-221, and Arg-230 residues
under the most energetically favorable simulation (Figure 4a).
Hydrogen bonds could be achieved between the hydroxyl
group at C-3 of BISA and either side chain of Tyr-231 or
Glu-221 and between the ketone group at C-4 of BISA and the
peptidyl amino backbone of Glu-221 (Figure 4a). Similarly,
BISA was also docked to the cAMP-binding B site of RIIb with
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Figure 3. Effects of bisabolangelone (BISA) on 8-[u-575]-cAMP binding to the regulatory subunit RIIb of protein kinase A (PKA). 8-[j-575]-cAMP (3mM) was
preincubated with cell-free RIIb polypeptides (1mg ml1) for 3 hours to reach stable fluorescence values under excitation at 575 nm and then treated with (a) BISA,
(b) Rp-adenosine 30,50-cyclic monophosphorothioate (Rp-cAMPS), or 5,6-dihydro-6-hydroxy-bisabolangelone (dhh-BISA) for 2 hours. Emission spectra are
represented as relative fluorescence units (RFU).
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Figure 4. Molecular docking of bisabolangelone (BISA) to the regulatory subunit RIIb of protein kinase A (PKA). Docking arrangements of BISA to the crystal
structure of human PKA (RIIb) were carried out using the Glide program. BISA in the refined models is represented by yellow color and its interacting residues
on the (a) cAMP-binding A site or (b) B site of PKA (RIIb) by green color. Hydrogen bonding between BISA and PKA (RIIb) is shown as a yellow dotted line.
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close contacts to Glu-350, Leu-351, Arg-359, Ala-360,
and Tyr-397 residues (Figure 4b). Hydrogen bonds could be
achieved between the hydroxyl group at C-3 of BISA and
either side chain of Glu-350 or Tyr-397 and between the
ketone group at C-4 of BISA and the peptidyl amino back-
bone of Leu-351 (Figure 4b). Moreover, the BISA-docking
simulations overlapped with those of the ligand cAMP
(Supplementary Figure S5 online).
BISA inhibits CREB activation and SOX9 induction in
melanocytes
As BISA inhibited a-MSH-induced PKA activation by blocking
cAMP binding to the regulatory subunit of PKA, we tested
whether BISA can affect downstream signal cascades in the
melanogenic process. Upon exposure to the cAMP elevator
a-MSH or db-cAMP alone, B16 or melan-a cells markedly
increased the Ser-133 phosphorylation of CREB, in which the
anti-p-CREB antibody also recognized the phosphorylated form
of activating transcription factor-1 (p-ATF-1) (Figure 5a and b).
p-ATF-1 is closely related to p-CREB in structure and function
(Hummler et al., 1994). BISA inhibited the CREB phosphory-
lation in a-MSH-activated B16 cells or db-cAMP-activated
melan-a cells (Figure 5a and b). Rp-cAMPS and H-89 also
inhibited db-cAMP-induced CREB phosphorylation in melan-a
cells (Figure 5b). We next transfected B16 cells with the CRE-
Luc construct, a luciferase reporter gene fused to three copies
of the CREB-responsive CRE motif, and then stimulated with
a-MSH in the presence of BISA. Upon exposure to a-MSH
alone, the transfected cells increased luciferase expression,
reporting CREB transcriptional activity up to about 10-fold over
basal levels (Figure 5c). BISA inhibited a-MSH-induced CREB
transcriptional activity in the cells (Figure 5c). PKA also
phosphorylates SOX9 in cAMP-elevated melanocytes, and
CREB transcriptional activity upregulates the expression of
the SOX9 gene (Passeron et al., 2007; Piera-Velazquez et al.,
2007). Upon exposure to a-MSH alone, B16 cells significantly
increased the Ser-181 phosphorylation of SOX9 (Figure 5d).
BISA inhibited a-MSH-induced SOX9 phosphorylation at an
early time point (Figure 5d) and also decreased cellular
induction of SOX9 in delayed kinetics (Figure 5e).
BISA and Rp-cAMPS suppress the a-MSH-induced expression of
MITF or the tyrosinase gene
CREB-responsive CRE motif and SOX9-binding DNA consensus
appear to be essential for maximal MITF induction in cAMP-
elevated melanocytes, even though the MITF promoter contains
several cis-acting elements (Udono et al., 2000; Passeron et al.,
2007). Upon exposure to a-MSH alone, B16 cells markedly
increased the protein levels of phosphorylated and nonphos-
phorylated MITFs (Figure 6a). BISA decreased a-MSH-inducible
protein levels of MITFs in cells, as did Rp-cAMPS (Figure 6a).
Accordingly, BISA attenuated a-MSH-induced messenger RNA
(mRNA) levels of MITF, in which Rp-cAMPS and H-89 were
also effective (Figure 6b). Moreover, BISA and Rp-cAMPS
inhibited a-MSH-increased promoter activity of the MITF gene
(Figure 6c), as determined using B16 cells transfected with the
MITF-Luc construct, a luciferase reporter containing MITF
promoter (2,200/þ 95) (Udono et al., 2000).
Second messenger cAMP also affects post-translational
modification of MITF, which is differently regulated from
CREB- or SOX9-mediated MITF induction in the melanogenic
pathways (Englaro et al., 1995; Khaled et al., 2002, 2003).
Upon exposure to a-MSH or PI3K inhibitor (wortmannin,
LY294002) alone, B16 cells decreased p-GSK3b levels with
the concomitant induction of tyrosinase mRNA (Supplementary
Figure S6a online). BISA did not affect the a-MSH-decreased
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Figure 5. Effects of bisabolangelone (BISA) on cAMP-responsive element-binding protein (CREB) activation and SOX9 induction. (a) B16 cells were pretreated
with BISA for 2 hours and stimulated with a-melanocyte-stimulating hormone (a-MSH) for 30 minutes in the presence of BISA. (b) Melan-a cells were pretreated
with BISA, Rp-adenosine 30,50-cyclic monophosphorothioate (Rp-cAMPS), or H-89 for 2 hours and stimulated with db-cAMP for 30 minutes in the presence of
BISA, Rp-cAMPS, or H-89. Cell extracts were subjected to western blot analysis (WB) with anti-p-CREB or anti-CREB antibody. (c) B16 cells were transfected with
CRE-Luc construct in combination with Renilla control vector and then stimulated with a-MSH for 20 hours in the presence of BISA. Cell extracts were subjected
to dual-luciferase assay. Firefly luciferase activity is represented as a relative fold after normalizing to Renilla activity. Data are mean±SD of three separate
experiments. #Po0.05 vs. media alone-added group. *Po0.05 vs. a-MSH alone-stimulated group. B16 cells were pretreated with BISA for 2 hours and stimulated
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or PI3K inhibitor–decreased p-GSK3b levels, but it consistently
attenuated the a-MSH-induced mRNA levels of tyrosinase with-
out affecting the PI3K inhibitor–induced tyrosinase expression
(Supplementary Figure S6a online). However, SB216763 as an
inhibitor of GSK3b activity suppressed not only a-MSH-induced
but also PI3K inhibitor–induced mRNA levels of tyrosinase
(Supplementary Figure S6a online). In another, cAMP activates
ERK-1/2 and then ribosomal S6 kinase 1, which phosphory-
lates MITF proteins marking for the proteasome-mediated
MITF degradation (Englaro et al., 1995; Wu et al., 2000).
Upon exposure to a-MSH alone, B16 cells phos-
phorylated ERK-1/2 and increased the mRNA levels of MITF
(Supplementary Figure S6b online). BISA did not affect a-MSH-
increased p-ERK-1/2 levels in the cells but still suppressed the
mRNA levels of MITF (Supplementary Figure S6b online).
Treatment with MEKK inhibitor PD98059 or U0126 decreased
a-MSH-induced ERK-1/2 phosphorylation without affecting the
mRNA levels of MITF (Supplementary Figure S6b online).
Therefore, BISA can suppress MITF induction in cAMP-elevated
melanocytes but not affect the PI3K/GSK3b or MEKK/ERK-1/2
pathway, conferring post-translational modification of MITF.
BISA decreases a-MSH-induced protein levels of tyrosinase
in melanocytes for antimelanogenic activity (Roh et al., 2011).
In the current study, BISA suppressed a-MSH- or db-cAMP-
induced protein levels of tyrosinase in B16 or melan-a cells,
in which dhh-BISA and Rp-cAMPS were also effective
(Supplementary Figure S7a and b online). Accordingly, BISA
attenuated a-MSH-induced mRNA levels of tyrosinase in B16
cells and also in melan-a cells, as did Rp-cAMPS and
H-89 (Supplementary Figure S7c and d online). Moreover,
BISA inhibited a-MSH-increased promoter activity of the
tyrosinase gene (Supplementary Figure S7e online), as deter-
mined using B16 cells transfected with the tyrosinase-Luc
construct, a luciferase reporter containing tyrosinase promoter
(2,236/þ 59) (Bertolotto et al., 1996). These results indicate
that BISA can downregulate the cAMP-induced expression
of tyrosinase gene at the transcription level.
DISCUSSION
cAMP is a key messenger in the melanogenic process, in which
the activation of PKA or CREB leads to upregulation of MITF
and tyrosinase genes. BISA and other sesquiterpene compounds
(a-bisabolol, 2,3-epoxyjuanislamin, parthenolide, and torillin)
suppress the expression of the tyrosinase gene for antimelano-
genic activity in cAMP-elevated melanocytes (Kim et al., 2008;
Ohguchi et al., 2009; Yun et al., 2009; Roh et al., 2011). How-
ever, their primary targets are largely unknown. In particular,
a-bisabolol decreases intracellular cAMP levels requisite for
CREB activation, which in turn downregulates the expression
of the MITF or tyrosinase gene (Kim et al., 2008). Moreover,
a-bisabolol reduces UV irradiation–induced skin pigmentation
of Asian women (Lee et al., 2010). In the current study, BISA
did not affect the cAMP levels in a-MSH-activated melanocytes
but inhibited cAMP-induced PKA activation in cells. BISA
specifically targeted the cAMP-binding site of PKA, as evi-
denced by its competitive displacement of 8-[j-575]-cAMP
bound to the regulatory subunit RIIb of PKA and its inhibitory
action on the a-MSH-induced dissociation of catalytic PKA
from an inactive holoenzyme complex. Accordingly, BISA fitted
well into the cAMP-binding A and B sites on the crystal
structure of PKA under the most energetically favorable simula-
tion. This unique mechanism of BISA affected PKA activity–
mediated CREB or SOX9 activation in cAMP-elevated B16 or
melan-a cells, thus suppressing the transcription of the MITF or
tyrosinase gene in the melanogenic pathway (Supplementary
Figure S8 online). However, BISA did not directly affect the
kinase activity of PKA with the catalytic subunit only, nor the
post-translational modification of MITF through the PI3K/GSK3b
and MEKK/ERK pathways in melanogenesis.
The PKA inhibitors for which a mechanism of action is
known can be divided into two general groups: (i) cAMP anta-
gonists targeting the regulatory subunit of the inactive holoen-
zyme complex, and (ii) competitive inhibitors targeting the
protein substrate– or cofactor ATP–binding site of the catalytic
subunit after dissociation from the inactive holoenzyme com-
plex. Rp-cAMPS is a PKA-directed cAMP antagonist, preventing
the dissociation and activation of the inactive holoenzyme
complex (Dostmann et al., 1990; Wu et al., 2004). In the
current study, we report that Rp-cAMPS suppressed the expres-
sion of the MITF or tyrosinase gene and inhibited melanin
production in cAMP-elevated melanocytes. Therefore, BISA
mimicked Rp-cAMP in the antimelanogenic mechanism, even
though the chemical structure of BISA is not related to those of
the agonist cAMP and the antagonist Rp-cAMPS. Peptide PKI
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Figure 6. Effects of bisabolangelone (BISA) on microphthalmia-associated transcription factor (MITF) expression. B16 cells were pretreated with BISA, Rp-
adenosine 30,50-cyclic monophosphorothioate (Rp-cAMPS), or H-89 for 2 hours and stimulated with a-melanocyte-stimulating hormone (a-MSH) for (a) 6 hours or
(b) 2 hours in the presence of BISA, Rp-cAMPS, or H-89. (a) Cell extracts were subjected to western blot analysis (WB) with anti-MITF or anti-GAPDH antibody.
(b) Total RNAs were subjected to reverse transcriptase–PCR (RT-PCR) analysis of MITF with b-actin as an internal control. (c) B16 cells were transfected with MITF-
Luc construct in combination with Renilla control vector. These transfected cells were stimulated with a-MSH for 20 hours in the presence of BISA or Rp-cAMPS.
Cell extracts were subjected to dual-luciferase assay. Firefly luciferase activity is represented as a relative fold after normalizing to Renilla activity. Data are
mean±SD of three separate experiments. #Po0.05 vs. media alone-added group. *Po0.05 vs. a-MSH alone-stimulated group.
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and chemical H-89 are typical PKA inhibitors that target the
catalytic subunit after dissociation from an inactive holoenzyme
complex (Knighton et al., 1991; Engh et al., 1996; Lochner and
Moolman, 2006; Zimmermann et al., 2008), thus acting on one
step later than the reference of Rp-cAMPS or BISA. PKI is
expressed in a variety of tissues and inhibits the kinase activity of
PKA after binding to the catalytic site as a pseudosubstrate
(Knighton et al., 1991; Zimmermann et al., 2008). PKI has
another domain structure that allows it to export the catalytic
subunit of PKA from the nucleus to the cytoplasm (Knighton
et al., 1991; Zimmermann et al., 2008), where catalytic PKA
can be converted to the inactive holoenzyme complex upon
reassociation with regulatory subunits. However, the
antimelanogenic activity of PKI has not been defined yet. H-89
binds to the ATP-binding site of PKA with the catalytic subunit
only and inhibits the kinase activity of PKA in a competitive
manner with respect to the cofactor ATP (Engh et al., 1996;
Lochner and Moolman, 2006). As ATP exists at millimolar levels
inside most cells, H-89 should be used at much higher
concentrations to inhibit the cellular activity of PKA than in
cell-free assays. H-89 also inhibits several protein kinases (MSK1,
S6K1, ROCK II) with a potency similar to or greater than that of
PKA (Davies et al., 2000). Therefore, H-89 is a nonspecific
inhibitor of PKA activity. In the current study, H-89 inhibited PKA
activity–mediated CREB activation in cAMP-elevated melano-
cytes and resultantly downregulated the expression of the MITF
or the tyrosinase gene. However, another cAMP/PKA-indepen-
dent mechanism is also suggested for the antimelanogenic
activity of H-89 (Cheli et al., 2009).
BISA exerts several pharmacological activities, including anti-
inflammatory action by inhibition of NF-kB or AP1 activation in
macrophages, antiulcer effects in animal models induced by
ethanol or Pylorus ligation, and acaricidal effects against Derma-
tophagoides farinae or D. pteronyssinus (Kang et al., 2006; Wang
et al., 2009; Jung et al., 2010). The molecular bases for these
bioactivities might be attributable in part to the primary target of
BISA, that is, cAMP-dependent PKA activation, as determined in
this study, as PKA is often activated by extracellular stressors or
various specific receptors, and its downstream substrate CREB
can affect the expression of many genes containing conserved
CRE elements adjacent to the TATA boxes (Zhang et al., 2005;
Sands and Palmer, 2008; Taylor et al., 2008).
In conclusion, the cAMP-binding site of PKA is a target of
BISA in the suppression of the MITF or the tyrosinase gene.
This mechanism of action had not been previously assigned
to any antimelanogenic chemicals/peptides, not even to
Rp-cAMPS with respect to melanocyte pigmentation. Finally,
this study suggests a therapeutic target against melanocyte-
specific hyperpigmented disorder, as evidenced from the
molecular basis of BISA or Rp-cAMPS in the inhibition of
the cAMP-induced melanogenic pathway.
MATERIALS AND METHODS
Materials
BISA was isolated from the dried roots of A. koreana as described
previously (Roh et al., 2011), and its purity (497%) was measured by
HPLC analysis (Supplementary Figure S9 online). Primary and
secondary antibodies used in this study were purchased from Abcam
(Cambridge, UK), Santa Cruz Biotech (Santa Cruz, CA) or Cell
Signaling Tech (Danver, MA). PKA (RIIb) polypeptides were pur-
chased from Proteintech group (Chicago, IL), and 8-[j-575]-cAMP
from BioLog (Bremen, Germany). All other chemicals including a-
MSH were otherwise purchased from Sigma-Aldrich (St Louis, MO).
Melanin quantification
Melanocytes were stimulated with a-MSH (100 nM), db-cAMP (3 mM),
forskolin (10mM), or IBMX (100mM) for 3–6 days. The cells were counted
and then disrupted in 0.85 N NaOH and 20% DMSO with heating at
80 1C. Absorbance values were measured at 405nm with synthetic
melanin as a standard, and then normalized to the cell numbers.
cAMP quantification
B16 cells were stimulated with a-MSH (100 nM) for 20 minutes. Cell
extracts were used to determine cAMP levels using an ELISA kit (R&D
Systems, Minneapolis, MN).
Immunoprecipitation
Cell extracts were incubated overnight with anti-PKA (RI) or anti-PKA
(RIIb) antibody (2mg), and then precipitated with protein G-sepharose
beads at 4 1C for 3 hours.
PKA/Kemptide assay
Enzyme sources were incubated with a mixture of 83mM Kemptide (Leu-
Arg-Arg-Ala-Ser-Leu-Gly), 20mM MOPS (pH 7.2), 13mM MgCl2,
150mM KCl, 100mM ATP, and 10mCi [g-32P]ATP at 30 1C for 20min-
utes. Aliquots of the reaction mixture were spotted onto P81 phospho-
cellulose papers, and then washed three times with 0.75% phosphoric
acid followed by one wash with 100% acetone. Radioactivities on the
papers were measured using a liquid scintillation counter.
Displacement assay of 8-[u-575]-cAMP
Fluorescent 8-[j-575]-cAMP (3mM) was incubated with cell-free RIIb
polypeptide of PKA (1mg 1 ml) for 3 hours to reach stable fluores-
cence values under excitation at 575 nm. Non-fluorescent BISA was
then treated for 2 hours, and followed by measuring relative fluores-
cence units emitted at 590–650 nm.
Molecular modeling
Docking simulations were carried out with the Glide program, and
the crystal structure of regulatory subunit RIIb of PKA was cited from
Protein Data Bank (1CX4). The receptor grid files were generated with
van der Waals scaling of the receptor at 1.0 at the center of the
cAMP-binding A or B site of PKA. The lowest energy conformation
was evaluated by the Glide docking score.
Statistical analysis
Data are expressed as mean±SD of at least three separate experiments
after the one-way analyses of variance followed by the Dunnett’s test.
Values of Po0.05 were considered as significantly different.
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